DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company operating in the healthcare and molecular diagnostics sector that entered the public markets in 2019 following a business combination with a blank check company. The company filed its annual report on Form 10-K on June 14, 2019, covering its operations as a newly public entity. Headquartered in La Jolla, California, DermTech develops non-invasive genomic tests for skin conditions, most notably its Pigmented Lesion Assay, which analyzes skin cell samples collected via adhesive patch to aid in melanoma detection as an alternative to surgical biopsy. Investors and analysts seeking full filing history, SPAC transaction details, and financial data on DMTK can sign up for access at SpacDesk.